LEO Pharma Strengthens US footprint and Global Development Team with appointment of Vice Presidents for Global Regulatory Affairs and Global Project Management
Ballerup, Denmark, May 10, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced the appointment of Beth-Anne Lang, Vice President and Head of Global Regulatory Affairs and Christine Garrett, Vice President and Head of Global Project Manage-ment. Both will join LEO Pharma on May 13.
Beth-Anne Lang and Christine Garrett will be based in Madison, New Jersey and be part of LEO Pharma’s Global Development Team. Beth-Anne’s main responsibility will be to lead and transform the regulatory into an even more modern and global organization and in this way support and accelerate LEO Pharma’s development of innovative dermatologic therapies to patients around the world. Christine Garrett’s main responsibility will be to lead a new program management organisation which will be key for LEO Pharma in order to strengthen the company’s global drug development capabilities and help make innovation available to patients faster.
LEO Pharma’s Global Development Team plays an important role in the execution of the company’s 2025 strategy. As part of the strategy, LEO Pharma R&D has launched a series of initiatives to raise the bar scientifically and build new capabilities within rare diseases, disease understanding and precision medicine within the company – supported by new ways of working with data and advanced analytics. Among other, this includes the recent addition of a new Translational Medicine Unit in Boston.
“LEO Pharma is building the world’s best dermatology R&D organisation, nothing less. The appointment of Beth-Anne Lang and Christine Garrett is a key milestone in achieving this ambition. Beth-Anne and Christine’s vast experience with global leadership roles in multi-country cross functional teams and diverse portfolios combined with their strong technical and scientific backgrounds will be critical in our constant quest for improving science to the benefit of patients,” says Christian Antoni, Head of Development, LEO Pharma.
Beth-Anne Lang comes to LEO Pharma with a broad regulatory experience in early and late development across several therapeutic areas and in biologics. Beth-Anne joins LEO Pharma from Takeda, where she has held a number of regulatory positions of increasing responsibility over the past 17 years, most recently as Vice President, Global Regulatory Affairs for marketed products. Among other, she has been a key driver in creating Takeda’s global regulatory strategies across multiple therapeutic areas and building the marketed products regulatory organization. She holds a Master in Business Administration from Marquette University and a Bachelor of Science in Food Science/Microbiology from the University of Illinois.
Christine Garrett joins LEO Pharma from a position as Global Project Leader for research & early development programs. Prior to this, she spent more than 16 years at Novartis in broad therapeutic areas across all phases of development, where she among other successfully built and led global project teams and cross-functional teams across research, development and commercial. Christine holds a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology, a Post-Graduate Certificate in Pharma Business Development & Licensing from the University of Manchester, A Master’s Certificate in Applied Project Management from Villanova University as well as Bachelor of Science in Chemistry from the Rochester Institute of Technology.
For further information, please contact:
LEO Pharma A/S
Trine Juul Wengel; Global External Communications
Tel.: +45 72 60 86 18
Information om LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million. For more information, go to: www.linkedin.com/company/leo-pharma or www.leo-pharma.com
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
New General Manager appointed to lead LEO Pharma across the Nordic region1.5.2019 10:12:37 CEST | Pressemeddelelse
Klaus Abel arrives to take the regional helm of the global medical dermatology leader
New data show that LEO Pharma’s Kyntheum® (brodalumab) sustains PASI 100 scores longer than ustekinumab for people with moderate-to-severe plaque psoriasis25.4.2019 09:12:24 CEST | Pressemeddelelse
Ballerup, Denmark, April 25, 2019: LEO Pharma A/S, a global leader in medical dermatology, today announced that new data presented this week at the 6th Congress of the Skin Inflammation and Psoriasis International Network (SPIN) in Paris demonstrate that more patients with moderate-to-severe psoriasis who received treatment with brodalumab maintained a PASI (Psoriasis Area Severity Index) 100 score for longer than those who were treated with ustekinumab over 52 weeks.
LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases11.4.2019 11:40:51 CEST | Pressemeddelelse
The large-scale IMI project will investigate the causes and mechanisms of Atopic Dermatitis and Psoriasis
LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology9.4.2019 10:00:56 CEST | Pressemeddelelse
Ballerup, April 9, 2019: LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations, today announced an expansion of the two companies’ partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.
LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment19.3.2019 10:33:23 CET | Pressemeddelelse
Andernach, DE, and Ballerup, DK, March 19, 2019: LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efficacy in patients.
Olivier Bohuon elected new chairman of LEO Pharma’s Board of Directors28.2.2019 00:10:03 CET | Pressemeddelelse
BALLERUP, Denmark, 28 February 2019 – LEO Pharma today announced changes to its Board of Directors. Olivier Bohuon is announced new chairman of the Board of Directors succeeding Jukka Pertola, who has decided to leave the Board. Member of the Board Anders Ekblom will assume a new position as vice chairman. In addition, John Weeks decided to not seek re-election.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum